[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Definium Therapeutics Inc (DFTX)

Definium Therapeutics Inc (DFTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Definium Therapeutics Eyes Key DT-120 Depression Data, Advances Anxiety Program

Definium Therapeutics (NASDAQ:DFTX) Chief Financial Officer Brandi Roberts said the company is preparing for several key clinical and regulatory milestones for DT-120, including anticipated Phase III data...

DFTX : 24.19 (+3.02%)
Definium Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference

Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological...

DFTX : 24.19 (+3.02%)
Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder

The primary endpoint will measure the change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) score at Week 6 between DT120 Orally Disintegrating Tablet (ODT) 100 µg and placebo...

DFTX : 24.19 (+3.02%)
Definium Therapeutics Announces New Employee Inducement Grants

Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes...

DFTX : 24.19 (+3.02%)
Definium Therapeutics Q1 Earnings Call Highlights

Definium Therapeutics (NASDAQ:DFTX) reported first-quarter 2026 financial results and outlined a series of near-term clinical milestones for its lead candidate, DT120 ODT, during a conference call held...

DFTX : 24.19 (+3.02%)
Definium Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

Three Phase 3 topline data readouts for DT120 ODT expected in the coming months DT120 ODT program expanded into PTSD with Phase 3 Haven study expected to initiate in...

DFTX : 24.19 (+3.02%)
Definium Therapeutics Prepares to Explain Why the Next Trial Will Be Different

Barchart Research What to Expect from DFTX Earnings DFTX Generated May 6, 2026 Current Price $23.42 EPS Estimate $$-0.47 Consensus Rating Strong Buy Average Move 4.80% Definium Therapeutics Prepares to...

DFTX : 24.19 (+3.02%)
Definium Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026

Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological...

DFTX : 24.19 (+3.02%)
These 3 Psychedelic Stocks Activated After Trump's Executive Order

Psychedelic drugs could get a big boost thanks to a recent executive order, and these firms all have promising candidates in line.

CMPS : 13.06 (+9.56%)
PSIL : 21.72 (+1.21%)
ATAI : 4.53 (+2.72%)
DFTX : 24.19 (+3.02%)
Definium Therapeutics Highlights DT120 ODT (Lysergide Tartrate) Clinical Advancements and Commercial Strategy at Investor and Analyst Day

MDD: Emerge topline data readout on track for late 2Q 2026; Ascend sites activated with first patient dosing anticipated in 2Q 2026 GAD: Voyage enrollment complete with...

DFTX : 24.19 (+3.02%)

Barchart Exclusives

Visa vs. Mastercard Stock: Using Barchart Data to Pick the Best Payments Giant Now
Visa and Mastercard dominate in payments, but one's stronger financials and dividend growth give it a slight edge. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.